At OCT DACH 2025, industry members noted that the implementation of AI in clinical trials must be carefully thought out.

Alkermes announced that the drug met its dual primary endpoints, however this was only in the two high dose cohorts and the data was “adjusted for multiplicity”. Image credit: MediaNews Group / Boston ...

If Roche's fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.

Gene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.

Eli Lilly will advance eloralintide to Phase III trials in obesity. Image credit: Michael Vi / Shutterstock.com Eli Lilly is advancing its obesity treatment candidate, which is an alternative to ...

Phesi, a patient-centric clinical data science company serving the global biopharmaceutical industry, won the Innovation award in the 2025 Clinical Trials Arena Excellence Awards. The award recognizes ...

Novo Nordisk said that the data suggests that the benefits of Wegovy go further than just weight loss in the patient population. Image credit: PJ McDonnell / Shutterstock.com. Novo Nordisk’s oral ...

Centessa is advancing ORX750 to pivotal trials based on the Phase IIa data. Image credit: SOPA Images /LightRocket via Getty Images Centessa Pharmaceuticals executives will be breathing a sigh of ...

The double-adjuvant arms produced significantly higher neutralising antibody titres on days 43 and 57 compared to the single-adjuvant arm. Credit: AnnaStills / Shutterstock.com. Valneva has reported ...

Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 in DMD from the FDA.

The trial aims to provide safety and efficacy data for submissions to regulatory agencies in the US and Europe. Credit: rathshiki / Shutterstock.com. Vir Biotechnology has concluded subject enrolment ...

This white paper offers a comprehensive overview of the global clinical trial landscape in therapeutic radiopharmaceuticals, providing insights into patient enrollment, trial distribution, and ...